Bleeding Disorders Treatment - Global Market Outlook (2017-2026)

Bleeding Disorders Treatment - Global Market Outlook (2017-2026)

  • Published: February 2018
  • ID: SMRC16988

According to Stratistics MRC,The Global Bleeding Disorders Treatment Market is accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026. Factors like growth in R&D investment for hemophilia products, inclination towards prophylactic treatment, increasing number of hemophilia patients, and the emergence of Biosimilars product are fuelling the market growth. Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth. Market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products. However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.

By type, Hemophilia is a genetic disorder characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII or IX deficiency. Patients with more severe haemophilia suffer more severe and more frequent bleeds. Hemophilia is inherited in an X-linked recessive manner. The main therapy to treat hemophilia A is concentrated FVIII product, as clotting factor or simply factor. DDAVP (desmopressin acetate) is the synthetic version of vasopressin, a natural antidiuretic hormone that helps stop bleeding. Emerging trends in therapies are efficacy and safety assessments of established extended half-life (EHL) factor products and interest in Clinical trial data from new/emerging EHL factor products and nonfactor replacement therapies.

Based on Drug, Von Willebrand disease (VWD) is a genetic disorder caused by missing or defective von Willebrand factor (VWF), a clotting protein. There are a few clotting factor concentrates that are rich in VWF. The management of patients affected by rare bleeding disorders (RBDs) is still a critical challenge. The development of alternative therapeutics, such as anti-tissue factor pathway inhibitor, ALN-AT3, and ACE910, for patients with hemophilia might also help in the treatment of patients affected by RBDs. FDA approved Vonvendi, which is produced with a genetically engineered Chinese hamster ovary cell line that expresses von Willebrand factor and the blood-clotting protein factor VIII.

North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.

Some of the key players in Global Bleeding Disorders Treatment Market are Alnylam Pharmaceuticals, Amgen, Inc, Baxalta (Now Shire), Bayer Pharmaceuticals, Biogen Inc, Bristol-Myers Squibb Company, Cangene Corporation, CSL Behring, Grifols SA, Janssen Pharmaceuticals, Novo Nordisk A/S, Octapharma, Pfizer Inc., Sanofi and Xenetic Biosciences, Inc.

Drugs Covered:
• Desmopressin
• Antifibrinolytics
• Fibrin Sealants
• Plasma-derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Other Drugs

Types Covered:
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Clotting Factor Deficiency

Therapies Covered:
• Medication Treatments
• Replacement Therapies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan       
    • China       
    • India       
    • Australia 
    • New Zealand     
    • South Korea      
    • Rest of Asia Pacific   
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary           
             
2 Preface 
           
 2.1 Abstract           
 2.2 Stake Holders          
 2.3 Research Scope          
 2.4 Research Methodology         
  2.4.1 Data Mining         
  2.4.2 Data Analysis         
  2.4.3 Data Validation         
  2.4.4 Research Approach         
 2.5 Research Sources          
  2.5.1 Primary Research Sources        
  2.5.2 Secondary Research Sources        
  2.5.3 Assumptions         
             
3 Market Trend Analysis   
       
 3.1 Introduction          
 3.2 Drivers           
 3.3 Restraints          
 3.4 Opportunities          
 3.5 Threats           
 3.6 Emerging Markets          
 3.7 Futuristic Market Scenario         
             
4 Porters Five Force Analysis          
 4.1 Bargaining power of suppliers         
 4.2 Bargaining power of buyers         
 4.3 Threat of substitutes         
 4.4 Threat of new entrants         
 4.5 Competitive rivalry          
             
5 Global Bleeding Disorders Treatment Market, By Drug     
  
 5.1 Introduction          
 5.2 Desmopressin          
 5.3 Antifibrinolytics          
 5.4 Fibrin Sealants          
 5.5 Plasma-derived Coagulation Factor Concentrates       
  5.5.1 Factor VIII         
  5.5.2 Factor IX          
  5.5.3 Factor for Von Willebrand Disease       
  5.5.4 Activated Prothrombin Complex Concentrate      
 5.6 Recombinant Coagulation Factor Concentrates       
  5.6.1 Factor VIII         
  5.6.2 Factor for Von Willebrand Disease       
  5.6.3 Factor IX          
 5.7 Other Drugs          
             
6 Global Bleeding Disorders Treatment Market, By Type       
 6.1 Introduction          
 6.2 Hemophilia A          
 6.3 Hemophilia B          
 6.4 Von Willebrand Disease         
 6.5 Clotting Factor Deficiency         
             
7 Global Bleeding Disorders Treatment Market, By Therapy     
  
 7.1 Introduction          
 7.2 Medication Treatments         
  7.2.1 Antifibrinolytic medicines        
  7.2.2 Iron supplementation        
  7.2.3 Desmopressin (DDAVP)        
 7.3 Replacement Therapies         
  7.3.1 Fresh frozen plasma transfusion therapy       
  7.3.2 Platelet transfusion therapy        
  7.3.3 Clotting factor replacement therapy       
             
8 Global Bleeding Disorders Treatment Market, By Geography       
 8.1 Introduction          
 8.2 North America          
  8.2.1 US          
  8.2.2 Canada          
  8.2.3 Mexico          
 8.3 Europe           
  8.3.1 Germany          
  8.3.2 UK          
  8.3.3 Italy          
  8.3.4 France          
  8.3.5 Spain          
  8.3.6 Rest of Europe         
 8.4 Asia Pacific          
  8.4.1 Japan          
  8.4.2 China          
  8.4.3 India          
  8.4.4 Australia          
  8.4.5 New Zealand         
  8.4.6 South Korea         
  8.4.7 Rest of Asia Pacific         
 8.5 South America          
  8.5.1 Argentina         
  8.5.2 Brazil          
  8.5.3 Chile          
  8.5.4 Rest of South America        
 8.6 Middle East & Africa         
  8.6.1 Saudi Arabia         
  8.6.2 UAE          
  8.6.3 Qatar          
  8.6.4 South Africa         
  8.6.5 Rest of Middle East & Africa        
             
9 Key Developments           
 9.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 9.2 Acquisitions & Mergers         
 9.3 New Product Launch         
 9.4 Expansions          
 9.5 Other Key Strategies         
             
10 Company Profiling     
      
 10.1 Alnylam Pharmaceuticals         
 10.2 Amgen, Inc          
 10.3 Baxalta (Now Shire)          
 10.4 Bayer Pharmaceuticals         
 10.5 Biogen Inc          
 10.6 Bristol-Myers Squibb Company        
 10.7 Cangene Corporation         
 10.8 CSL Behring          
 10.9 Grifols SA          
 10.10 Janssen Pharmaceuticals         
 10.11 Novo Nordisk A/S           
 10.12 Octapharma          
 10.13 Pfizer Inc.          
 10.14 Sanofi           
 10.15 Xenetic Biosciences, Inc      


List of Tables             
1 Global Bleeding Disorders Treatment Market Outlook, By Region (2016-2026) ($MN)    
2 Global Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)     
3 Global Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)    
4 Global Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)    
5 Global Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)    
6 Global Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
7 Global Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
8 Global Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
9 Global Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)  
10 Global Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN) 
11 Global Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN) 
12 Global Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
13 Global Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)  
14 Global Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
15 Global Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)    
16 Global Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)     
17 Global Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)    
18 Global Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)    
19 Global Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)   
20 Global Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)   
21 Global Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)    
22 Global Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)   
23 Global Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)   
24 Global Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)   
25 Global Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)   
26 Global Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)   
27 Global Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN) 
28 Global Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)  
29 Global Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)  
30 North America Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)    
31 North America Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)    
32 North America Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)   
33 North America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)   
34 North America Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)   
35 North America Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
36 North America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
37 North America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
38 North America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
39 North America Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
40 North America Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
41 North America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
42 North America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
43 North America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
44 North America Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)   
45 North America Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)    
46 North America Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)   
47 North America Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)   
48 North America Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)  
49 North America Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)  
50 North America Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)    
51 North America Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)  
52 North America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)  
53 North America Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)  
54 North America Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)  
55 North America Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)  
56 North America Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
57 North America Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)  
58 North America Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN) 
59 Europe Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)    
60 Europe Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)     
61 Europe Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)    
62 Europe Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)   
63 Europe Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)    
64 Europe Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
65 Europe Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
66 Europe Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
67 Europe Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)  
68 Europe Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN) 
69 Europe Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN) 
70 Europe Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
71 Europe Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN)  
72 Europe Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
73 Europe Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)    
74 Europe Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)     
75 Europe Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)    
76 Europe Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)    
77 Europe Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)   
78 Europe Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)   
79 Europe Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)    
80 Europe Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)   
81 Europe Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)   
82 Europe Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)   
83 Europe Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)   
84 Europe Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)   
85 Europe Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN) 
86 Europe Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)  
87 Europe Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN)  
88 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)    
89 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)    
90 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)   
91 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)   
92 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)   
93 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
94 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
95 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
96 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
97 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
98 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
99 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)    
100 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
101 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)    
102 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)   
103 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)    
104 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)   
105 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)   
106 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)  
107 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)  
108 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)    
109 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)  
110 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)  
111 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)   
112 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)  
113 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)  
114 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN) 
115 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)  
116 Asia Pacific Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN) 
117 South America Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)    
118 South America Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)    
119 South America Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)   
120 South America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)   
121 South America Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)   
122 South America Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
123 South America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
124 South America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
125 South America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
126 South America Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
127 South America Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
128 South America Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
129 South America Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
130 South America Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
131 South America Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)   
132 South America Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)    
133 South America Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)   
134 South America Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)   
135 South America Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN)  
136 South America Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN)  
137 South America Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)    
138 South America Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)  
139 South America Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN)  
140 South America Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)  
141 South America Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)  
142 South America Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)  
143 South America Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
144 South America Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN)  
145 South America Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN) 
146 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Country (2016-2026) ($MN)   
147 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Drug (2016-2026) ($MN)   
148 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Desmopressin (2016-2026) ($MN)  
149 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Antifibrinolytics (2016-2026) ($MN)  
150 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Fibrin Sealants (2016-2026) ($MN)  
151 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2016-2026) ($MN)
152 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
153 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
154 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
155 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Activated Prothrombin Complex Concentrate (2016-2026) ($MN)
156 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Recombinant Coagulation Factor Concentrates (2016-2026) ($MN)
157 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor VIII (2016-2026) ($MN)   
158 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor for Von Willebrand Disease (2016-2026) ($MN) 
159 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Factor IX (2016-2026) ($MN)   
160 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Other Drugs (2016-2026) ($MN)   
161 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Type (2016-2026) ($MN)   
162 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Hemophilia A (2016-2026) ($MN)  
163 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Hemophilia B (2016-2026) ($MN)  
164 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Von Willebrand Disease (2016-2026) ($MN) 
165 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Clotting Factor Deficiency (2016-2026) ($MN) 
166 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Therapy (2016-2026) ($MN)   
167 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Medication Treatments (2016-2026) ($MN)  
168 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Antifibrinolytic medicines (2016-2026) ($MN) 
169 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Iron supplementation (2016-2026) ($MN)  
170 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Desmopressin (DDAVP) (2016-2026) ($MN)  
171 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Replacement Therapies (2016-2026) ($MN)  
172 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Fresh frozen plasma transfusion therapy (2016-2026) ($MN)
173 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Platelet transfusion therapy (2016-2026) ($MN) 
174 Middle East & Africa Bleeding Disorders Treatment Market Outlook, By Clotting factor replacement therapy (2016-2026) ($MN) 

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials